Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets

Innovative drug discovery approaches are currently needed to rejuvenate the shrinking product pipelines of the pharmaceutical companies across the globe. Here a theme is presented – the use of central nervous system (CNS) drugs as leads for non-CNS targets. The approach is related to the use of exis...

Descripción completa

Detalles Bibliográficos
Autor principal: Kharkar, Prashant S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2014
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961999/
https://www.ncbi.nlm.nih.gov/pubmed/24715979
http://dx.doi.org/10.12688/f1000research.3-40.v2
_version_ 1782308371751239680
author Kharkar, Prashant S.
author_facet Kharkar, Prashant S.
author_sort Kharkar, Prashant S.
collection PubMed
description Innovative drug discovery approaches are currently needed to rejuvenate the shrinking product pipelines of the pharmaceutical companies across the globe. Here a theme is presented – the use of central nervous system (CNS) drugs as leads for non-CNS targets. The approach is related to the use of existing drugs for new indications. Suitable chemical modifications of the CNS drugs abolish their CNS penetration. These novel analogs may then be screened for activity against non-CNS targets. Careful selection of the appropriate structural modifications remains the key to success.
format Online
Article
Text
id pubmed-3961999
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-39619992014-04-07 Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets Kharkar, Prashant S. F1000Res Commentary Innovative drug discovery approaches are currently needed to rejuvenate the shrinking product pipelines of the pharmaceutical companies across the globe. Here a theme is presented – the use of central nervous system (CNS) drugs as leads for non-CNS targets. The approach is related to the use of existing drugs for new indications. Suitable chemical modifications of the CNS drugs abolish their CNS penetration. These novel analogs may then be screened for activity against non-CNS targets. Careful selection of the appropriate structural modifications remains the key to success. F1000Research 2014-03-21 /pmc/articles/PMC3961999/ /pubmed/24715979 http://dx.doi.org/10.12688/f1000research.3-40.v2 Text en Copyright: © 2014 Kharkar PS http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/publicdomain/zero/1.0/ Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).
spellingShingle Commentary
Kharkar, Prashant S.
Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets
title Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets
title_full Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets
title_fullStr Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets
title_full_unstemmed Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets
title_short Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets
title_sort drugs acting on central nervous system (cns) targets as leads for non-cns targets
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961999/
https://www.ncbi.nlm.nih.gov/pubmed/24715979
http://dx.doi.org/10.12688/f1000research.3-40.v2
work_keys_str_mv AT kharkarprashants drugsactingoncentralnervoussystemcnstargetsasleadsfornoncnstargets

Ejemplares similares